A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport(®) or Prograf(®) preparations of tacrolimus

BACKGROUND: The use of generic formulations of immunosuppressive drugs in place of brand name drugs offers considerable cost savings. Brand name tacrolimus (Prograf(®)) came off patent in April 2008. However, published evidence supporting therapeutic equivalence of generic formulations of tacrolimus...

Descripción completa

Detalles Bibliográficos
Autores principales: Connor, Andrew, Prowse, Andrew, Newell, Paul, Rowe, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094386/
https://www.ncbi.nlm.nih.gov/pubmed/27818747
http://dx.doi.org/10.1093/ckj/sfs154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094386/
https://www.ncbi.nlm.nih.gov/pubmed/27818747
http://dx.doi.org/10.1093/ckj/sfs154

Ejemplares similares